Heteroaryl Amide Compounds for Human STING Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current STING agonists, such as cyclic dinucleotides and small molecules like DMXAA and CMA, are ineffective in activating human STING, limiting their potential in inducing interferons for treating infectious diseases and cancer, as they fail to bind and activate the human receptor effectively.
Innovation Solution
Development of heteroaryl amide compounds that specifically activate the human STING receptor, leading to the upregulation of IRF3 and NFκB pathways, thereby producing interferons and proinflammatory cytokines, which are essential for immune response activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclic dinucleotides or small molecules like DMXAA and CMA are used as STING agonists, then the STING pathway can be activated, but they are ineffective in activating human STING receptor
Solution Approach 1:
The patent modifies the chemical structure of STING agonists by changing molecular parameters such as introducing heteroaryl amide groups, adjusting ring structures, and modifying substituent patterns. These parameter changes enable the compounds to specifically bind to and activate human STING receptor while maintaining the desired immunomodulatory effects.
Solution Approach 2:
The invention introduces specific local structural features into the agonist molecules, such as heteroaryl amide moieties at particular positions, to enhance binding affinity and selectivity for human STING. These localized structural modifications allow the compounds to differentiate between species-specific receptor variations.
2Reliability
If type I interferons are used as therapeutic agents, then antiviral and anticancer effects can be achieved, but the half-life is short and systemic toxicities occur
Solution Approach 1:
The patent employs STING agonists to preliminarily activate the STING pathway, which then triggers endogenous production of type I interferons and proinflammatory cytokines. This preliminary activation of the immune pathway leads to sustained therapeutic effects without requiring continuous administration of exogenous interferons, thereby extending the duration of action.
Solution Approach 2:
The STING agonist compounds serve as catalysts that initiate a self-sustaining immune response. Once the STING pathway is activated, the body's own immune system produces interferons and cytokines, creating a self-amplifying therapeutic effect that reduces the need for repeated dosing and minimizes systemic toxicity associated with continuous exogenous interferon administration.
3Reliability
If high doses of interferons are administered, then therapeutic effects are enhanced, but dose-limiting systemic toxicities increase
Solution Approach 1:
The STING agonist compounds act as intermediaries that indirectly induce interferon production through pathway activation rather than direct interferon administration. This intermediary approach allows for amplified therapeutic effects at lower doses, as the activated STING pathway triggers robust endogenous interferon production without the immediate toxicities associated with high-dose exogenous interferon therapy.
Data Source
AI summary
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.